drugset
drugset / Trial / NCT02218489

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489 ↗

Phase 2 Completed 206 enrolled Kala Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.

Timeline

Start
2014-07
Primary completion
2015-12
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Loteprednol Etabonate Other / unclassified 0.25 % Topical

Indications

blepharitis